SCHEMBL280137

SCHEMBL280137

Cc1ccc(C(=O)CS(=O)(=O)Cc2ccncn2)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.44
ADORA2B P29275 2/20 0.44
DAO P14920 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
RAB9A P51151 5/20 0.36
NPC1 O15118 3/20 0.36
ALDH1A1 P00352 3/20 0.34
HPGD P15428 2/20 0.34
POLB P06746 2/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
NAMPT P43490 2/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279741 0.73 HSD11B1 (0.49) DAOL3MBTL1RAB9ANPC1ALDH1A1
SCHEMBL279739 0.73 ALDH1A1 (0.47) ADORA2AADORA2BDAOL3MBTL1RAB9A
SCHEMBL280148 0.70 ADORA2A (0.43) ADORA2AADORA2BDAOL3MBTL1RAB9A
SCHEMBL280382 0.69 HSD11B1 (0.45) ADORA2AADORA2BDAOL3MBTL1RAB9A
SCHEMBL1272091 0.66 HSP90AA1 (0.40) ALDH1A1POLBNAMPTTDP1P2RX7
SCHEMBL28596505 0.66 P2RX7 (0.39) ADORA2AADORA2BKMT2ANAMPTHTT
SCHEMBL279938 0.66 ADORA2A (0.36) ADORA2AADORA2BDAOL3MBTL1RAB9A
SCHEMBL280368 0.65 KMT2A (0.44) ADORA2AADORA2BDAOL3MBTL1RAB9A
SCHEMBL2045567 0.65 GSK3B (0.50) DAOL3MBTL1RAB9ANPC1ALDH1A1
SCHEMBL15979700 0.64 DAO (0.61) DAOL3MBTL1RAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL ADORA2A 726/4885ADORA2B 454/4885DAO 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.